MORRIS PLAINS, N.J., Nov. 16, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 7 presentations involving 4 of its product candidates have been accepted for presentation at the 53rd American Society of Hematology (ASH) Annual Meeting, scheduled for December 10 – 13, 2011, in San Diego, CA. The abstracts include oral and poster presentations across a spectrum of hematologic malignancies and autoimmune disease. The schedule and meeting places for the presentations, together with the publication numbers, are listed below:
